We aim to create a general drug design engine with AI that can be applied across various disease areas, not just targeting a single indication.

We aim to create technologies and platform capabilities that are broadly useful, enabling new mechanistic insights and potentially curing diseases.

By 2025, we will be able to design full antibodies and enzymes through advanced AI models, revolutionizing drug development.

The advancements in AI, such as AlphaFold, are revolutionizing fields like medicine, enabling us to design proteins that can potentially cure diseases like cancer.

We expect to see meaningful progress against diseases with AI-assisted tools in the near future.

In the future, the pharmaceutical industry will integrate AI into drug design, making it an essential tool for biology and chemistry.

AI has the potential to improve diagnosis and treatment in healthcare, moving beyond just drug discovery.

AI has the potential to revolutionize healthcare by detecting and preventing diseases early at scale, which is why we founded Fountain Life, a center to help people understand their health before it's too late.

We're trying to build an artificial intelligence that is smarter and more capable than humans in every way, aiming to solve the biggest problems facing the world and create significant new businesses.